# WGS — GeneDx Holdings Corp · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** WGS  
**Sources:** 17  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-wgs-genedx-holdings-corp-catalysts-narrative-risks-10430

---

## GeneDx Holdings Corp. (WGS) — Research Snapshot as of 2026-10-31

### Current Snapshot
GeneDx Holdings Corp. (Nasdaq: WGS) is a genomic diagnostics company providing whole exome/whole genome sequencing and AI-supported interpretation for rare disease, pediatric, hereditary, and cancer testing. It was formerly Sema4 (which acquired GeneDx from OPKO Health in 2022 and renamed itself). [[5]](https://www.marketbeat.com/earnings/reports/2026-11-9-genedx-holdings-corp-stock/), [[8]](https://www.marketbeat.com/stocks/NASDAQ/WGS/), [[18]](https://stockanalysis.com/stocks/wgs/)

As of the last close on Friday, October 30, 2026, the stock traded at **$69.06**, down 2.76% on the day, with a market capitalization of **$2.06 billion**. [[8]](https://www.marketbeat.com/stocks/NASDAQ/WGS/), [[10]](https://stockanalysis.com/stocks/wgs/forecast/), [[12]](https://stockinvest.us/stock/WGS) The stock has a beta of 1.97 and a 52-week range of $32.21–$170.87, indicating high volatility and a significant pullback from its highs. [[8]](https://www.marketbeat.com/stocks/NASDAQ/WGS/), [[18]](https://stockanalysis.com/stocks/wgs/)

---

### Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-wgs-genedx-holdings-corp-catalysts-narrative-risks-10430 (free to sign up)._